CETP
Signaling Pathway Map
Research Area
- Inhibitory Selectivity
- Solubility
| Catalog No. | Product Name | Solubility(25°C) | ||
|---|---|---|---|---|
| Water | DMSO | Alcohol | ||
| S2748 | Anacetrapib (MK-0859) | <1 mg/mL | 127 mg/mL | 127 mg/mL |
| S2792 | Torcetrapib | <1 mg/mL | 120 mg/mL | 6 mg/mL |
| S2925 | Evacetrapib (LY2484595) | <1 mg/mL | 12.8 mg/mL | 12.8 mg/mL |
| S2772 | Dalcetrapib (JTT-705, RO4607381) | <1 mg/mL | 78 mg/mL | 78 mg/mL |
- CETP Inhibitors (4)
| Catalog No. | Information | Product Use Citations | Product Validations |
|---|---|---|---|
| S2748 |
Anacetrapib (MK-0859)Anacetrapib (MK0859) is a potent, selective, reversible rhCETP and mutant CETP(C13S) inhibitor with IC50 of 7.9 nM and 11.8 nM, increases HDL-C and decreases LDL-C, does not increase aldosterone or blood pressure. Phase 3. |
||
| S2792 |
TorcetrapibTorcetrapib is a CETP inhibitor with IC50 of 37 nM, elevates HDL-C and reduces nonHDL-C in plasma. Phase 3. |
||
| S2925 |
Evacetrapib (LY2484595)Evacetrapib (LY2484595) is a potent and selective inhibitor of CETP with IC50 of 5.5 nM, elevates HDL cholesterol without increases in aldosterone or blood pressure. Phase 3. |
||
| S2772 |
Dalcetrapib (JTT-705, RO4607381)Dalcetrapib (JTT-705) is a rhCETP inhibitor with IC50 of 0.2 μM that increases the plasma HDL cholesterol. Phase 3. |
